Earnings Call Insights: Halozyme Therapeutics (HALO) Q1 2026
Management view
-
“We started 2026 with exceptional momentum,” said President, CEO & Director Helen Torley, pointing to “strong conviction in the 2026 to 2028 financial guidance” and saying partner deal activity and Phase I activity are “bending the curve in
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
